Discussing the Future of Personalized Medicine with Biotech Experts

28/12/2016 - 2 minutes

Personalized medicine has been a popular topic in the last few years, but when will it materialize? Experts discussed the current challenges at Labiotech Refresh.

Jean-Pol Detiffe is the CEO of OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment. In his opinion, one of the main challenges in the field is that “biology is complex and a successful test cannot only rely on genes“. His company addresses it by also looking at RNA and methylation. He also highlighted liquid biopsy as a big trend in the field: “we have developed a personalized blood test to see if cancer is coming back, focusing on following up with the patients“.

Marjolaine Barldo is Head EMEA at Agendia, a company with a diagnostic test that can reduce the use of chemotherapy by 46% in patients with breast cancer. Mammaprint is one of the first diagnostic tests to show robust clinical results that could lead to reimbursement,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member